FIELD: medicine.
SUBSTANCE: method involves administering diacerine influencing DNA synthesis for reducing keratinocytes proliferation without changing their vital activity, inhibiting interleukines IL-1,IL-6 and α-TNF (tumor necrosis factor).
EFFECT: enhanced effectiveness of treatment.
11 cl, 7 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DIOXOANTHRACENE SULPHONATE DERIVATIVES | 2008 |
|
RU2482109C2 |
| THERAPEUTIC AGENT FOR INHIBITION OF PHOSPHODIESTERASE AND ASSOCIATED PATHOLOGICAL DISORDERS | 2018 |
|
RU2815010C2 |
| METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
| COMPOSITION FOR TREATING ARTHRITIS | 2009 |
|
RU2563360C2 |
| USE OF N-(6,8,8-TRIMETHYL-8,9-DIHYDROFURO[3,2-H]QUINOLIN-5-YL)ACETAMIDE AS AN AGENT FOR PHOTOTHERAPY OF PSORIASIS AND PSORIATIC ARTHRITIS | 2018 |
|
RU2686692C1 |
| AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
| AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
| INTERLEUKIN-15 ANTAGONIST PEPTIDE | 2009 |
|
RU2506270C2 |
| METHOD OF INHIBITING EXPRESSION OF IL-22 IN ACTIVATED T-CELLS | 2013 |
|
RU2663448C2 |
| METHODS AND COMPOSITIONS FOR TREATING HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | 2012 |
|
RU2603050C2 |
Authors
Dates
2005-12-27—Published
2001-01-08—Filed